Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20043186 | 0.82 | KCNH2 (0.34) | — | |
| SCHEMBL29324287 | 0.81 | CYP1A2 (0.48) | CYP1A2PTPN1KDM4ELMNAPOLB | |
| SCHEMBL4058013 | 0.81 | CYP1A2 (0.56) | CYP1A2PTPN1KDM4ELMNAPOLB | |
| SCHEMBL15958525 | 0.79 | CYP1A2 (0.46) | CYP1A2PTPN1KDM4ELMNAPOLB | |
| SCHEMBL7246121 | 0.79 | PTPN1 (0.49) | CYP1A2PTPN1KDM4ELMNAPOLB | |
| SCHEMBL23502499 | 0.78 | HPGDS (0.32) | — | |
| SCHEMBL20047495 | 0.76 | TERT (0.33) | — | |
| SCHEMBL24633577 | 0.74 | CYP1A2 (0.48) | CYP1A2PTPN1KDM4ELMNAPOLB | |
| SCHEMBL23797313 | 0.74 | PTPN1 (0.51) | CYP1A2PTPN1KDM4ELMNAPOLB | |
| SCHEMBL13676595 | 0.74 | PDGFRB (0.46) | CYP1A2KDM4EPOLBCASP6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CYP1A2 311/4885PTPN1 1449/4885KDM4E 4232/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | CYP1A2 311/4885PTPN1 1449/4885KDM4E 4232/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP1A2 424/4885PTPN1 3891/4885KDM4E 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.